FOXA1 and posterior cortical atrophy: Therefore, FOXA1-targeted treatment for PCa patients must follow a path that does not endanger the patient’s life and occurs under conditions that reasonably exceed the expected therapeutic exposure; thereby, partial tendencies can be accepted in early clinical development.